Ten-year users of Slim Fast meal replacement products experienced a 33-pound greater reduction compared to non-users, George Blackburn, MD, Beth Israel Deaconess Hospital, Boston, et al., report at the North American Association for the Study of Obesity Oct. 11-15 in Ft. Lauderdale. Forty-four men and 86 women were provided with meal plans and diet plan instructions were followed for 10 years. At the study's conclusion, "the weight change from baseline was - 3.1 ± kg for men and - 2.4 ± kg for women, researchers report, adding matched controls gained roughly 12.1 kg over the same time period. The positive study results may alleviate 1FTC's stance that consumers should "be skeptical about products that claim they will keep weight off you permanently." Three other studies presented at the conference similarly touted Slim Fast's benefits...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
New US FDA drugs center director George Tidmarsh’s data-centric comments at a Reagan-Udall Foundation meeting on unapproved fluoride products could suggest patients’ and caregivers’ experiences will carry less weight in benefit-risk decisions under his leadership.
Pink Sheet reporter and editors discuss the potential impact George Tidmarsh could have as director of the US FDA Center for Drug Evaluation and Research and the issues threatening the future of Sarepta’s gene therapy Elevidys.
The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.
